Protagonist Therapeutics (PTGX) EBT Margin (2017 - 2026)
Protagonist Therapeutics (PTGX) reported EBT Margin of 4.05% for Q1 2026, up 4520.0% on a YoY basis from 0.09% in Q1 2025, and up 100.69% sequentially from 587.84% in Q4 2025.
Protagonist Therapeutics (PTGX) EBT Margin (2017 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 10 years of EBT Margin data on file, last reported at 4.05% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 4520.0% year-over-year to 4.05%; the trailing twelve-month figure through Mar 2026 stood at 155.78% (down 18400.0% YoY), and the FY2025 full-year result was 281.01%, down 34532.0% from the prior year.
- EBT Margin advanced to 4.05% in Q1 2026, from 587.84% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 82.63% in Q1 2024 to a low of 4966.12% in Q2 2022.
- A 5-year average of 713.51% and a median of 424.05% in 2022 frame the typical range for EBT Margin.
- Peak annual rise in EBT Margin reached 12750 bps in 2022, while the deepest fall reached 360445 bps in 2022.
- Tracing PTGX's EBT Margin over 5 years: stood at 4966.12% in 2022, then surged by 101 bps to 54.67% in 2023, then jumped by 48 bps to 80.99% in 2024, then tumbled by 826 bps to 587.84% in 2025, then soared by 101 bps to 4.05% in 2026.
- Business Quant data shows PTGX's EBT Margin at 4.05% in Q1 2026, 587.84% in Q4 2025, and 834.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | 4.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.05% |
| Dec 31, 2025 | -587.84% |
| Sep 30, 2025 | -834.87% |
| Jun 30, 2025 | -623.86% |
| Mar 31, 2025 | -41.15% |
| Dec 31, 2024 | 80.99% |
| Sep 30, 2024 | -719.36% |
| Jun 30, 2024 | -750.95% |
| Mar 31, 2024 | 82.63% |
| Dec 31, 2023 | 54.67% |
| Jun 30, 2022 | -4,966.12% |
| Mar 31, 2022 | -260.26% |
| Dec 31, 2021 | -428.30% |
| Sep 30, 2021 | -328.64% |
| Jun 30, 2021 | -1,361.68% |
| Mar 31, 2021 | -387.75% |
| Dec 31, 2020 | -334.27% |
| Sep 30, 2020 | -59.20% |
| Jun 30, 2020 | -294.23% |
| Mar 31, 2020 | -545.76% |